Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karakatsanis Stamatis J, Bouzani Maria, Symeonidis Argyris, Angelopoulou Maria K, Papageorgiou Sotirios G, Michail Michail, Gainaru Gabriella, Kourti Georgia, Sachanas Sotirios, Kalpadakis Christina, Katodritou Eirini, Leonidopoulou Theoni, Kotsianidis Ioannis, Hatzimichael Eleftheria, Kotsopoulou Maria, Dimou Maria, Variamis Eleni, Boutsis Dimitrios, Kanellias Nick, Dimopoulou Maria N, Michali Evridiki, Karianakis George, Tsirkinidis Pantelis, Vadikolia Chryssa, Poziopoulos Christos, Pigaditou Anna, Vrakidou Effimia, Economopoulos Theophanis, Kyriazopoulou Lydia, Siakantaris Marina P, Kyrtsonis Marie-Christine, Anargyrou Konstantinos, Papaioannou Maria, Hatjiharissi Evdoxia, Vervessou Elissavet, Tsirogianni Maria, Palassopoulou Maria, Stefanoudaki Ekaterini, Zikos Panayiotis, Tsirigotis Panayiotis, Tsourouflis Gerassimos, Assimakopoulou Theodora, Verrou Evgenia, Papadaki Helen, Lampropoulou Polixeni, Dimopoulos Meletios-Athanasios, Pappa Vassiliki, Konstantopoulos Kostas, Karmiris Themis, Roussou Paraskevi, Panayiotidis Panayiotis, Pangalis Gerassimos A, Vassilakopoulos Theodoros P, Hellenic Cooperative Lymphoma Group
Аннотация
PATIENTS AND METHODS: We retrospectively studied our cohort of consecutively treated PMLBCL patients, focusing on their treatment density, in order to determine possible differences in treatment outcomes.
RESULTS: CIT, in the form of both R-CHOP-21 as well as R-CHOP-14 (or similar regimens), is highly active in PMLBCL, with low rates of early treatment failure. In our cohort of patients, R-CHOP-14 did not result in a meaningful improvement of freedom from progression (FFP) or overall survival (OS).
CONCLUSION: Both R-CHOP-14 and R-CHOP-21 are probably equally effective in PMLBCL, yet further, prospective, randomized studies are warranted to clarify whether dose-dense regimens can be associated with better disease control and long-term results.